Key learnings:

• SurgaColl announced the completion of a £3.1 million Series A round in January 2018, which includes investments from GM&C Life Sciences Fund and Julz Co.
• The investment will enable the medical device company to progress its pipeline of collagen-based regenerative products and build up its team.
• William (Bill) Allan, Chief Executive Officer at SurgaColl, sat down with Biotech and Money to discuss the funding round and the company’s objectives over the year ahead.

to read the full article, please follow the link